drugset / Trial / NCT05419479
Switch Maintenance in Pancreatic
Phase 1/2
Suspended
46 enrolled
James Cleary, MD, PhD
Arcus Biosciences, Inc. · collabLustgarten Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body. This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells. The names of the study drugs involved in this study are: * Domvanalimab (also known as AB154) * Zimberelimab (also known as AB122) * APX005M
Timeline
- Start
- 2022-11-30
- Primary completion
- 2026-05-17
- Completion
- 2032-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Domvanalimab | Monoclonal antibody | — | Intravenous |
| Comparator | Irinotecan | Small molecule | — | Intravenous |
| Comparator | Leucovorin | Small molecule | — | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |
| Comparator | fluorouracil | Small molecule | — | Intravenous |
| Subject | sotigalimab | Monoclonal antibody | — | Intravenous |